Defective hydroxylation of bufuralol associated with side‐effects of the drug in poor metabolisers [letter]
Open Access
- 1 May 1982
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 13 (5), 750-752
- https://doi.org/10.1111/j.1365-2125.1982.tb01453.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.British Journal of Clinical Pharmacology, 1981
- Determination of bufuralol and its major metabolites in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Influence of renal failure on the hepatic clearance of bufuralol in manJournal of Pharmacokinetics and Biopharmaceutics, 1980
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- Polymorphism in drug metabolism.BMJ, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Determination of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detectionJournal of Mass Spectrometry, 1976
- Ro 3-4787, A NEW β-ADRENOCEPTOR BLOCKING AGENT: STUDIES IN NORMAL VOLUNTEERSBritish Journal of Clinical Pharmacology, 1974